Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239748 | 0.89 | TAAR1 (0.50) | TAAR1DRD1DRD2DRD5FNTA | |
| Water SCHEMBL10416041 | 0.84 | FNTA (0.54) | TAAR1DRD1DRD2DRD5FNTA | |
| SCHEMBL2946237 | 0.82 | DRD1 (0.65) | TAAR1DRD1DRD2DRD5ADRA1D | |
| SCHEMBL10414481 | 0.81 | ADRA2A (0.43) | TAAR1FNTAFNTB | |
| SCHEMBL18634398 | 0.81 | CHRNA7 (0.53) | DRD1DRD2DRD5OPRM1OPRD1 | |
| SCHEMBL1798685 | 0.81 | CYP1A2 (0.53) | TAAR1 | |
| SCHEMBL9184067 | 0.80 | TAAR1 (0.43) | TAAR1DRD1DRD2DRD5FNTA | |
| SCHEMBL29332470 | 0.80 | TAAR1 (0.50) | TAAR1DRD1DRD2DRD5FNTA | |
| SCHEMBL13503895 | 0.79 | PRCP (0.54) | DRD1DRD2DRD5 | |
| Hydrochloric Acid SCHEMBL6167962 | 0.79 | CYP1A2 (0.52) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214570-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214570-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2007018460-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1060163-B1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE CO CHEM PHARM FAB (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-6903118-B1 | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | KLINGE PHARMA GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| US-20020151539-A1 | Novel heterocyclic compounds | JORGENSEN TINE KROGH (DK) | 2002-10-17 | — | — | US | disclosed |
| US-6391890-B1 | ANALGESICS, ANTIINFLAMMATORY AGENTS, NON-INSULIN DEPENDENT DIABETES | NOVO NORDISK A/S (DK) | 2002-05-21 | — | — | US | disclosed |
| US-6130217-A | ANTITUMOR | PFIZER INC (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0691962-B1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AG (DE) | 2000-09-13 | — | — | EP | disclosed |
| US-6054458-A | Heterocyclic compounds | NOVONORDISKALS (DK) | 2000-04-25 | — | — | US | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| WO-1994022846-A1 | COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| EP-0575890-A1 | Fumaric acid salts of quinoline derivatives to overcome MDR in cancer treatment | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-12-29 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0535152-A1 | BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS. | SCHERING CORP (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| WO-1992000293-A1 | BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214570-A1 | Therapeutic Agents | NLN, BDNF, GAP43 | TAAR1 792/4885DRD1 2673/4885DRD2 2108/4885 |
| US-20020151539-A1 | Novel heterocyclic compounds | IAPP, GPR119, NPY1R | TAAR1 1040/4885DRD1 1017/4885DRD2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.